Status:
COMPLETED
JAK2 Mutation May Predict Response and Guide First Line Treatment in Rheumatoid Arthritis
Lead Sponsor:
Mansoura University
Conditions:
Response Assessment in Newly Diagnosed RA Patients at 3rd Month Was Evaluated by DAS28 and ACR in Relation to JAK Expression
Eligibility:
All Genders
18-80 years
Phase:
NA
Brief Summary
This study included 76 newly diagnosed RA patients and 50 matched controls. Basal JAK2 mutation was assessed by PCR in blood samples, TNF-α and IL 6 were measured by ELISA in serum of patients and con...
Detailed Description
PCR detection of the JAK-2 V617F mutation using ASO specific PCR Genetic marker: The detection of jak2 V617F mutation were done by using the following primers (JAK2 Reverse: 5' CTGAATAGTCCTACAGTGTTTT...
Eligibility Criteria
Inclusion
- New case RA patients
- good liver and renal function
Exclusion
- Other autoimmune diss
- Malignancy
- Active viral infection
- pregnancy and lactation
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2020
Estimated Enrollment :
76 Patients enrolled
Trial Details
Trial ID
NCT04667988
Start Date
January 1 2019
End Date
May 1 2020
Last Update
December 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mansoura University Hospital
Al Mansurah, Egypt